Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-K
26 avr. 2023 12h15 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Aridis Provides Corporate Update
31 mars 2023 19h00 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on...
Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock
14 mars 2023 09h45 HE
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company, today announced that it has entered into a definitive agreement for...
Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients
13 mars 2023 08h00 HE
|
Aridis Pharmaceuticals, Inc.
The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif.,...
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
25 janv. 2023 16h05 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of...
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
17 janv. 2023 16h30 HE
|
Aridis Pharmaceuticals, Inc.
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 ...
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
28 déc. 2022 08h30 HE
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12 déc. 2022 08h05 HE
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in...
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
12 déc. 2022 07h00 HE
|
Aridis Pharmaceuticals, Inc.
Los Gatos, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in...
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
05 déc. 2022 07h00 HE
|
Aridis Pharmaceuticals, Inc.
The Sudan Ebola and Marburg mAb programs were awarded approximately $190 million of BARDA funding covering manufacturing, efficacy and safety evaluations, and regulatory approval Los Gatos, Calif.,...